{
    "success": true,
    "data": {
        "ucits": false,
        "type": "ETP",
        "leverage": true,
        "derivatives": true,
        "swaps": true,
        "inverse": true,
        "replication_method": "synthetic",
        "complex_factors": [
            "Leveraged investment (3x)",
            "Inverse exposure",
            "Use of swaps",
            "Daily rebalancing with compounding effect",
            "High risk indicator (7/7)"
        ],
        "classification": "complex",
        "supporting_data": "The product is a '3x Short Moderna Daily ETP Securities', indicating significant leverage (3x) and inverse exposure, which are inherently complex. The KIID explicitly states: 'You are about to purchase a product that is not simple and may be difficult to understand.' It also mentions the use of a swap with a Swap Provider, introducing counterparty risk. The daily reset of the leverage factor leads to a 'compounding effect' which deviates from the underlying asset's performance over periods longer than one day, making the payoff structure difficult for retail investors to understand. The product is classified with the highest risk indicator (7 out of 7), further emphasizing its complexity. The document also highlights that the investor may lose their entire investment if the firm is unable to pay out, which is linked to the collateral provided by the Swap Provider. The recommended holding period is 'One (1) day', underscoring the short-term, speculative nature, which is a hallmark of complex products.  The inherent complexity driven by the leveraged and inverse structure, reliance on swaps, and the compounding effect of daily rebalancing clearly points towards a complex classification under MiFID II, requiring a comprehension alert in the KIID."
    }
}